Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
Heidelberg, Germany, April 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an update on its operations in response to the continued spread of the COVID-19 coronavirus pandemic. Affimed also announced that it will host a conference call on Tuesday, April 28, 2020 at 8:30 a.m. ET to discuss its full year 2019 financial results and recent corporate developments. “Our priority at this time is to ensure the safety and health of our employees, their families, our partners and the patients we serve, while also maintaining continuity of our business and ongoing clinical trials,” said Dr. Adi Hoess, Affimed’s CEO. “The unprecedented and expanding COVID-19 global health crisis will require an extraordinary amount of healthcare resources that we expect will have an impact on our clinical trials. As circumstances around the COVID-19 pandemic continue to rapidly evolve, we are c
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)GlobeNewswire
- Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
- Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)GlobeNewswire
- Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerGlobeNewswire
AFMD
Earnings
- 11/14/24 - Beat
AFMD
Sec Filings
- 12/17/24 - Form 6-K
- 11/14/24 - Form 6-K
- 11/12/24 - Form EFFECT
- AFMD's page on the SEC website